Oculis AG (OCS) - חוב לטווח ארוך להון

This chart of the market valuation for Oaktree Specialty Lending (OCS) captures the 0.01 metric, confirming the company's status as a leading innovator in ophthalmology with high physician trust. The business relies on the development of patent-protected non-invasive drops for retinal edema. The technology stack is based on the application of AI in molecular design and bioreactors, although final drug verification remains with the experts.

This indicator determines the degree of the business's long-term financial autonomy by comparing liabilities with maturities exceeding one year against total equity. Analyzing the ratio of long-term debt to equity allows for an assessment of Oaktree Specialty Lending (OCS) resilience to crises, which is critical when financing costly ESG projects focused on the ecological disposal of chemicals and the implementation of biodegradable packaging in biopharmaceutical production.